1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis

  • February 2015
  • 79 pages
  • ID: 2670949
  • Format: PDF

Summary

Table of Contents

Search Inside

Competitor Analysis: VEGF & VEGF-R Antibodies 2015 – Biosimilars and Biosuperiors of Avastin and Lucentis

This Competitive Intelligence Report about VEGF and VEGF-R Antibodies 2015 - Biosimilars and Biosuperiors of Avastin and Lucentis provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) used to treat various cancers and ophthalmic diseases as of February 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The family of antibody products targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) has become highly successful in clinical and economic terms. Avastin and Lucentis as the first generation products and Eylea and Zaltrap as the second wave of VEGF products followed by the anti-VEGF-R2 antibody Cyramzy generated combined product sales of more than US$ 13.7 bln in the year 2014. Strong driver of sales growth are the pipelines in a product leading to approval in more and more cancer and eye disease indications.

The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation "biobetter or biosuperior" molecules as well as of biosimilar copies of the originator products with the most advanced molecules already in phase III trials.

The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes, Target / Mechanism of Action, Class of Compound, Company, Product Category, Indication, R&D Stage and additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019

  • $ 2000
  • January 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H1 ...

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2019

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline ...

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2019

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2019

  • $ 3500
  • March 2019

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H1 2019SummaryIntegrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha o ...


ref:plp2015

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on